Cytology News and Research

RSS

Cytology is the study of cells using a microscope.

Study demonstrates ability of cobas HPV Test to detect HPV-16, HPV-18 genotypes linked to cervical cancer

Roche announced that a study published online today in the American Journal of Clinical Pathology demonstrated the ability of the cobas HPV Test to individually detect HPV-16 and HPV-18, two of the highest risk HPV genotypes causing 70 percent of cervical cancer cases.

From Roche Sequencing and Life Science 25 Feb 2011

NCC, BD to implement cervical cancer early detection program for underserved women in Peru

The National Cancer Coalition and BD (Becton, Dickinson and Company), a leading global medical technology company, are pleased to announce the implementation of a cervical cancer early detection program to benefit 75,000 underserved women in Peru. With a goal to reduce the high cervical cancer mortality levels in the mountainous region surrounding Cusco, this extensive three-year program is set to conduct liquid-based cytology exams utilizing the BD SurePath™ Liquid-based Pap Test System.

From BD (Becton, Dickinson and Company) 5 Feb 2011

IASLC publishes new international multidisciplinary classification for lung adenocarcinoma

Three of the world's top lung associations have published a new international multidisciplinary classification of lung adenocarcinoma, the first revision to the classification in six years.

1 Feb 2011

UH researchers to discuss computational surgery at MITIE

More than a dozen University of Houston (UH) researchers will be making presentations, ranging from robot-assisted surgery techniques to improving heart and breast surgery procedures, at the third annual international conference in computational surgery Jan. 26-28. The symposium will be held at The Methodist Hospital Research Institute (TMHRI) in Houston.

25 Jan 2011

Gen-Probe's APTIMA HPV assay effective for cervical cancer screening: FASE study

In a study published today in the International Journal of Cancer, Gen-Probe's APTIMA HPV Assay provided a better combination of sensitivity and specificity than HPV DNA- or cytology-based tests for cervical cancer screening.

18 Nov 2010

USPTO issues patent to Aperio's digital pathology system

Aperio, the global leader in providing digital pathology solutions that enhance patient safety and improve patient care, announced today that the United States Patent and Trademark Office has issued the company patent No. 7,787,674 entitled, "Systems and Methods for Viewing Three Dimensional Virtual Slides."

11 Nov 2010

S.A.N.E. Vax calls for federal approval of reliable HPV genotyping test in cervical cancer prevention programs

In a letter addressed to Dr. Harold E. Varmus, director of the NCI, and Dr. Margaret Hamburg, FDA commissioner, Ms. Norma Erickson, president of S.A.N.E. Vax, Inc., requested that these two federal agencies recommend a reliable human papillomavirus (HPV) genotyping test to support the national virology-based cervical cancer prevention program for patient care. Erickson stated: "The NCI knows reliable HPV genotyping is based on using a PCR system with short target sequencing."

9 Nov 2010

Annual conventional Pap smear is cost effective to reduce cancer incidence and mortality

A study of the options for reducing cancer incidence and mortality among women who have been treated for precancerous cervical lesions found that an annual conventional Pap smear is a cost effective strategy.

21 Oct 2010

Biomoda extends pilot clinical trial of CyPath assay for early-stage lung cancer detection

Cancer diagnostics company Biomoda, Inc. today announced in its new monthly President's Column, posted at www.biomoda.com, that it is extending the pilot clinical trial of its CyPath diagnostic assay for the detection of early-stage lung cancer to recruit additional participants for the positive control group, patients who have been diagnosed with lung cancer but have not yet begun treatment for the disease.

8 Oct 2010

Researchers develop new technique to detect lung cancer

Early detection is critical for improving cancer survival rates. Yet, one of the deadliest cancers in the United States, lung cancer, is notoriously difficult to detect in its early stages.

8 Oct 2010

Veracyte presents FNA clinical trial data at International Thyroid Congress

Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial data from its large-scale, prospective, multi-center clinical trial were presented today at the 14th International Thyroid Congress, held in Paris, France.

16 Sep 2010

Biomoda joins Saccomanno Research Institute to advance CyPath technology for cancer detection

Cancer diagnostics company Biomoda, Inc. is working with the Saccomanno Research Institute to advance Biomoda's patented system for measuring the photon emission rate of CyPath-stained cells to detect early-stage lung cancer.

8 Sep 2010

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.

26 Aug 2010

Norwegian cervical screening program begins reimbursing for liquid-based cytology

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that on July 1, 2010, the Norwegian cervical screening program began reimbursing for liquid-based cytology (LBC).

6 Aug 2010

Enzo Clinical Labs appointed as participating laboratory in Empire BlueCross BlueShield provider network

Enzo Biochem Inc.'s wholly-owned subsidiary, Enzo Clinical Labs, Inc., and Empire BlueCross BlueShield, the largest health insurer in New York State, today jointly announced that effective August 1, 2010 Enzo Clinical Labs will be a participating laboratory in the Empire provider network for the metropolitan New York area.

3 Aug 2010

Patent application for inexpensive CyPath assay filed by Biomoda

Cancer diagnostics company Biomoda,filed a U.S. patent application on a quantitative method for scoring cells labeled with the CyPath® assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.

21 Jul 2010

Study compares denture stomatitis genes with whole transcriptome for salivary biomarker analysis

The goal of the study was to compare whole-transcriptome, mucosal gene expression in Candida albicans (a parasitic fungus that can infect the mouth) associated chronic denture stomatitis to that of healthy oral mucosa and perform proteomic analyses of potential salivary biomarkers. Denture stomatitis is a condition in which the mucosa underneath a denture becomes inflamed and sometimes painful.

16 Jul 2010

Cervical cancer vaccine could reduce number of cases from 3,000 to less than 700 every year

The cervical cancer vaccine could prevent even more cases of the disease in England than previously thought, UK scientists have found.

15 Jul 2010

QIAGEN's digene HPV Test improves cervical cancer control: Study

A study released today "online first" in Cancer Causes & Control demonstrates that human papillomavirus testing, using QIAGEN's digene HPV Test, improved cervical cancer control compared to routine Pap (cytology) testing among 50,000 women across Mexico, the first country in Latin America to implement a national screening program for the high-risk types of HPV that can cause cervical cancer.

From QIAGEN Manchester Limited 13 Jul 2010

OPMEDIC GROUP third-quarter revenue up 9% to $3.899 million

OPMEDIC GROUP Inc., a healthcare-related company in fertility, laboratories and surgeries providing services and facilities to patients and surgeons, is pleased to announce financial results for the third quarter ended May 31, 2010.

9 Jul 2010